InfliximabDrug ineffective and off-label use: case report

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2025年 / 2051卷 / 1期

关键词：

D O I：

10.1007/s40278-025-79667-7

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：147 / 147

相关论文

共 50 条

[1] DoxorubicinDrug ineffective and off-label use: case report
Reactions Weekly, 2022, 1902 (1) : 183 - 183
[2] Multiple drugsDrugs ineffective and off-label use: case report
Reactions Weekly, 2022, 1904 (1) : 305 - 305
[3] Ipilimumab/nivolumabDrug ineffective and off-label use: case report
Reactions Weekly, 2022, 1898 (1) : 232 - 232
[4] AdalimumabTreatment ineffective following off-label use: case report
Reactions Weekly, 2022, 1912 (1) : 17 - 17
[5] BaricitinibDrug ineffective in unapproved condition following off-label use: case report
Reactions Weekly, 2023, 1938 (1) : 306 - 306
[6] Mutiple drugsVarious toxicities, drug ineffective and off-label use: case report
Reactions Weekly, 2023, 1974 (1) : 272 - 272
[7] InfliximabDrug ineffective : case report
Reactions Weekly, 2023, 1959 (1) : 330 - 330
[8] RituximabHypogammaglobulinaemia and off-label use: case report
Reactions Weekly, 2023, 1956 (1) : 453 - 453
[9] PosaconazoleHepatotoxicity and off-label use: case report
Reactions Weekly, 2024, 2021 (1) : 447 - 447
[10] PasireotideHyperglycaemia and off-label use: case report
Reactions Weekly, 2021, 1876 (1) : 273 - 273

← 1 2 3 4 5 →